Dr. Shore is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
823 82nd Pkwy
Myrtle Beach, SC 29572Phone+1 843-449-1010Fax+1 843-497-6171
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1986 - 1990
- OtherClass of 1984
- Duke University School of MedicineClass of 1983
Certifications & Licensure
- SC State Medical License 1994 - 2025
- NY State Medical License 1985 - 2008
- NJ State Medical License 1990 - 1995
- American Board of Urology Urology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACS) American College of Surgeons
Clinical Trials
- MCS in the Treatment of Lower Urinary Tract Symptoms Start of enrollment: 2010 Jul 01
- A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
- Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Start of enrollment: 2012 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK.Neal D Shore, Ugo De Giorgi, Stephen J Freedland
The Journal of Urology. 2025-01-01 - 1 citationsDarolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.Fred Saad, Egils Vjaters, Neal Shore, David Olmos, Nianzeng Xing
Journal of Clinical Oncology. 2024-12-20 - Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recur...Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka
Future Oncology. 2024-12-12
Lectures
- Real-World Clinical Outcomes with Radium-223 in Metastatic Castration-Resistant Prostate Cancer - Neal ShoreLarge Urology Group Practice Association, Chicago, Illinois - 11/1/2012
- Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Press Mentions
- The EMBARK Trial: An Interview with Neal D. Shore, MDMay 19th, 2023
- Pfizer, Astellas Pharma' Xtandi Combo Therapy Cuts Risk of Metastasis, Death by 58 Percent in Prostate CancerMay 1st, 2023
- StockwatchMay 1st, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: